All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Cidara Therapeutics, BARDA partner on flu prevention candidate CD388 development, up to $339M deal
Government funding, infectious disease, manufacturing agreement, milestone payments - Read more

European Commission, HIPRA sign COVID-19 vaccine procurement contract for 4 million doses
Manufacturing agreement, vaccine, infectious disease - Read more

THE GOOD
Clinical Trials

Ovid Therapeutics reports positive Ph1 data for OV329 GABA-aminotransferase inhibitor in drug-resistant epilepsy, advances to Ph2
Small molecule, neurological, GABA-AT inhibitor, epilepsy, biomarker study - Read more

Guard Therapeutics' RMC-035 shows renoprotective effects in Ph2a AKITA study for acute kidney injury after surgery
Small molecule, kidney disease, acute kidney injury, cardiac surgery, renoprotective therapy - Read more

Arvinas ARV-102 LRRK2-targeting PROTAC reduces Parkinson's disease biomarkers in Ph1 trial after 14 days
PROTAC, neurological, Parkinson's disease, LRRK2 target, protein degradation - Read more

PRESENTED BY YOU?
Get the attention of 2200+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Fundraises

Kihealth raises $5M Seed, precision diagnostics for early diabetes detection
Precision diagnostics, biomarker discovery, diabetes, autoimmune, metabolic disease - Read more

Repairon raises undisclosed Series A, regenerative cell therapies for heart failure
Cell therapy, cardiovascular, regenerative medicine, clinical-stage - Read more

QuantHealth raises undisclosed strategic investment, AI-driven clinical trial simulation platform
AI/ML platform, clinical trial platform, data analytics, AI-driven - Read more

Egetis Therapeutics raises $19M directed share issue, tiratricol NDA development
Rare disease, clinical-stage, small molecule, regulatory approval - Read more

Palisade Bio raises $138M public offering for autoimmune/inflammatory disease therapeutics
Autoimmune, inflammatory, small molecule, clinical-stage - Read more

Enanta Pharmaceuticals raises $74.8M public offering, developing small molecule antiviral drugs
Small molecule, viral infections, immunological diseases, clinical-stage - Read more

THE GOOD
Regulatory

FDA launches pilot program offering priority review for generic drugmakers using domestic manufacturing and testing
Generic drugs, regulatory, strategic, operational - Read more

GSK successfully appeals UK PMCPA’s industry discredit ruling regarding COVID vaccine press releases
COVID-19 vaccine, infectious disease, regulatory, operational - Read more

THE BAD
Layoffs

CSL Vifor cuts 55 jobs at King of Prussia site as part of 15% global workforce reduction
Iron deficiency therapy, hematology, cost reduction, operational, workforce restructuring - Read more

THE BAD
Politics & Policy

CMS finalizes expanded orphan drug protections from IRA price negotiations, potentially delaying billions in savings
Rare disease, oncology, regulatory, strategic, financial - Read more

THE BAD
Strategic Plans

Rocket Pharmaceuticals withdraws FDA application for Fanca-cel gene therapy targeting fanconi anemia amid strategic reprioritization
Gene therapy, rare disease, lentiviral vector, fanconi anemia, bone marrow failure, FDA withdrawal - Read more

THE UGLY
Politics & Policy

Former NIAID Director Marrazzo fired after filing whistleblower complaint against HHS leadership under RFK Jr.
Infectious disease, regulatory, operational, strategic - Read more

U.K. advocacy groups call for antitrust probe into Eli Lilly, AstraZeneca, Merck & Co. coordinated investment exodus
Regulatory, competitive, strategic, major transaction - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here